Circulating immune cells and immune checkpoints expression in non-Alcoholic SteatoHepatitis and its association with Inflammatory Bowel Disease

1 Service of Immunology, Hospital Universitario Marqués de Valdecilla (HUMV) & Instituto de investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria
Patricia Lamadrid Perojo, Marcos López Hoyos.

INTRODUCTION

Non Alcoholic Fatty Liver Disease (NAFLD) occurs in certain immune-mediated diseases such as inflammatory Bowel Disease (IBD). Non Alcoholic SteatoHepatitis (NASH) is its most aggressive form. In both, an inflammatory pathogenic mechanism mediated by TNF-α, Th1 and Th17 is attributed. Immune Mediated Inflammatory Diseases (IMIDs) also gather some properties that may justify both the co-occurrence of several IMIDs in the same individual and the family aggregation of multiple IMIDs, 4) comorbidities and common complications generated by the inflammatory chronic effects, 5) and a common response to pharmacological agents with shared therapeutic targets within the inflammatory pathway (deregulated cytokines). Research regarding this issue is certainly scarce and biased. In the current project, a complete study of the number of cell populations of the immune response both innate and adaptive is carried out. A differentiated response may be responsible for the evolution towards NAFLD in patients with IBD.

HYPOTHESIS AND OBJECTIVES

NASH stands for a liver inflammatory disease with an important metabolic risk component, but an exacerbated immune response may be an independent cause of its occurrence. It is possible that the coexistence of another immune-mediated diseases, such as IBD, plays a role in the NASH triggering regardless metabolic factors. The study of different cellular populations of the immune response in peripheral blood, both effector and regulatory, can help to differentiate IBD from both NASH and NASH coexisting with IBD, as well as to define cellular markers of clinical utility. The three main objectives are defined as:

• To set up the flow cytometry protocols for diverse cell populations of immune response: effector, memory, naïve T cells, regulatory T cells (Treg) and helper T cell subtypes; B lymphocytes during their different maturational stages, myeloid-derived suppressor cells (MDSC) and innate lymphoid cells (ILC), aside from to measure the expression level of several immune checkpoints (ICP).
• To monitorize these blood populations of 3 groups of patients with immunomodulated diseases: NASH, NASH coexisting with IBD, and IBD.
• To search for disease specific patterns of circulating cell populations of the immune response which may explain possibly related pathogenic mechanisms.

MATERIAL AND METHODS

One hundred and seventy seven patients have been recruited as part of the present study (45 women and 132 men). The study members belong to two different groups: healthy controls (n=149) and patients with inflammatory liver diseases (n=28). The patients group is also divided into three different subgroups: 10 individuals with NASH, 9 with NASH+IBD and 9 with IBD. The control group was recruited from Marqués de Valdecilla University Hospital Blood Bank (Santander, Spain) and the group of patients from the Digestive Service of that hospital. Every member of this study has signed an informed consent. The current study is part of the FIS P18/031034 project. The following table show the clinical and demographic characteristics of the 177 individuals studied.

<table>
<thead>
<tr>
<th>Clinical and demographic parameters</th>
<th>NASH (n=28)</th>
<th>NASH+IBD (n=9)</th>
<th>IBD (n=9)</th>
<th>Controls (n=149)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Women</td>
<td>57%</td>
<td>57%</td>
<td>55%</td>
<td>57%</td>
</tr>
<tr>
<td>Age</td>
<td>45±10.51</td>
<td>41±22.36</td>
<td>39±10.51</td>
<td>37±10.51</td>
</tr>
<tr>
<td>Alkaline Phosphatase (mU/L)</td>
<td>567±362</td>
<td>406±117.2</td>
<td>326±78</td>
<td>424±117.2</td>
</tr>
<tr>
<td>C Reactive Protein (mg/L)</td>
<td>10.4±4.11</td>
<td>1.4±0.49</td>
<td>1.4±0.49</td>
<td>0.98±0.49</td>
</tr>
<tr>
<td>IgG</td>
<td>15.9±7.3</td>
<td>15.7±3.1</td>
<td>15.7±3.1</td>
<td>15.7±3.1</td>
</tr>
<tr>
<td>IgM</td>
<td>1.4±0.49</td>
<td>1.4±0.49</td>
<td>1.4±0.49</td>
<td>1.4±0.49</td>
</tr>
<tr>
<td>Diabetes (Yes/No)</td>
<td>3/5</td>
<td>2/3</td>
<td>2/3</td>
<td>3/5</td>
</tr>
<tr>
<td>HbA1c (Yes/No)</td>
<td>1.3/1.3</td>
<td>1.3/1.3</td>
<td>1.3/1.3</td>
<td>1.3/1.3</td>
</tr>
<tr>
<td>C-Reactive Protein (mg/L)</td>
<td>10.4±4.11</td>
<td>10.4±4.11</td>
<td>10.4±4.11</td>
<td>10.4±4.11</td>
</tr>
<tr>
<td>Lymphocytes (x10^9/L)</td>
<td>2.7±0.7</td>
<td>2.7±0.7</td>
<td>2.7±0.7</td>
<td>2.7±0.7</td>
</tr>
<tr>
<td>Neutrophils (x10^9/L)</td>
<td>0.9±0.2</td>
<td>0.9±0.2</td>
<td>0.9±0.2</td>
<td>0.9±0.2</td>
</tr>
</tbody>
</table>

Peripheral blood mononuclear cells (PBMC) from heparin blood have been isolated by density gradient for immunophenotyping and analysis by flow cytometry. Specific monoclonal antibodies for the study of effector, memory, naïve T cells, Th cell subtypes, B lymphocytes during their different maturational stages, MDSC and ILC were employed. The expression level of several immune checkpoints has been measured twice: basal and at 3 days after PHA stimulation. Stimulation with PHA + rIL-2, rIL-15, and addition of peptide to the intracytoplasmic quantification of Th cytokines has been also performed. The different cell populations have been acquired with the Cytoflex flow cytometer and analyzed with the Kaluza software (Beckman Coulter). Statistical was performed with the statistical package IBM SPSS 22.0 and GraphPad Prism 6.

RESULTS AND DISCUSSION

Figure 1. Representative flow cytometry analysis of effector, memory and naïve T cells (A), the three suppressive myeloid cells subpopulations of interest (MD-MDC, PMN-MDC and e-MDC) (B), and helper T cells subtypes (C, D).

Figure 2. Representative flow cytometry analysis of the three main innate lymphoid cells subpopulations (ILC1, ILC2 and ILC3) (A), and the expression level of several immune checkpoints (CTLA-4, LAG-3, BTLA, PD-1, ICOS-L, PD-L1) and its difference between day 0 and after 3 days of PHA stimulation (B).

Figure 3. Flow plots comparing three patients groups (NASH, NASH coexisting with IBD and IBD) with several subpopulations analysed: Treg (A), Th17 (B), naïve B cells (C), plasma B cells (D), ILC1 (E) and ILC3 (F).

CONCLUSIONS

• The flow cytometry protocols have been set up with several monoclonal antibodies panels for the labeling and quantification of different immune effector and regulatory cell populations, from which has been successfully identified effector, memory and naïve T cells, regulatory T cells (Treg) and helper T cell subtypes; B lymphocytes during their different maturational stages, myeloid-derived suppressor cells (MDSC) and innate lymphoid cells (ILC), as well as the expression level of several immune checkpoints and its difference after three days of PHA stimulation.
• In patients with NASH, a large T activation (TEMRA) and increased B cells in immature stages have been highlighted.
• In IBD patients, a decreased T activation (T naive) with a noticeable inflammatory environment defined by Th17 and ILC3, and increased B cells in mature stages (memory and plasma B cells) have been showed.
• The coexistence of both pathologies in the NASH+IBD group has showed T activation as in NASH, a marked inflammatory environment (decreased ratio Treg/Th17, increased ILC3 and decreased ILC2) and a generalized B cell populations decrease.

FURTHER RESEARCH

This is a proof of concept small study to set up the methodology to characterize the main immune cell subtypes and to implement it in a larger study in the context of IMID project at HUM Valdecilla.

Acknowledgements

I would like to thank the Immunity Service of IDIVAL and HUM Valdecilla, as well as the Digestive Service of the hospital for making this project possible.

References

1. Van Herck, MA et al., Frontiers in Immunology, 2019; 10:305 (20).
3. He B et al. BMC Immunology, 2017; 18:133 (9).